Phaseline

Companies › ArriVent BioPharma

ArriVent BioPharma: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Firmonertinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Metastatic Non-Small Cell Lung Cancer; Non-Small-Cell Lung Cancer; Non-Small Cell Lung Cancer (NSCLC)Dec 2026
ARR-002–Phase 1Ovarian CancerAug 2027
MRG007 (ARR-217)–Phase 1Locally Advanced or Metastatic Solid TumorsMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05364073FirmonertinibPhase 1Non-Small Cell Lung Cancer (NSCLC)OncologyDec 2026
NCT07755436ARR-002Phase 1Ovarian CancerOncologyAug 2027
NCT05607550FirmonertinibPhase 3Metastatic Non-Small Cell Lung CancerOncologyFeb 2028
NCT07066657MRG007 (ARR-217)Phase 1Locally Advanced or Metastatic Solid TumorsOncologyMar 2028
NCT07185997FirmonertinibPhase 3Non-Small-Cell Lung CancerOncologyFeb 2029

From the company's SEC filings

Cash and short-term investments of $393m on 2026-09-30; operating cash outflow about $164m a year; runway about 29 months at that burn, to Feb 2029; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 12 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Jiangsu Alphamab Biopharmaceuticals Nanjing Sanhome Pharmaceutical Black Diamond Therapeutics Jiangsu Aosaikang Pharmaceutical HC Biopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.